Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Ibrahim Vedat BayogluMustafa Oktay Tarhan

Abstract

Mesothelin is a cell surface glycoprotein that is overexpressed in various malignancies. Recent studies have revealed that mesothelin plays an oncogenic role in tumor growth and drug resistance through the Wnt/NF-κB/PI3K/Akt signaling pathways. Herein, the expression of mesothelin in HER2-positive and triple-negative breast cancer (TNBC) has been correlated with prognosis. A total of 430 patients with breast cancer treated between 2006 and 2013 were retrospectively reviewed; of these, 123 cases were considered TNBC (n=71; 58%) or were positive for HER2 (n=52; 42%). Mesothelin expression was assessed by immunohistochemistry. Of the patients with TNBC, 30 (42.3%) were positive for mesothelin expression, compared to only two (3.8%) of the HER2-positive cases. As most HER2-positive tumors were negative for mesothelin staining, statistical analysis was not performed. Median overall survival (OS) was 70.1 months for patients with TNBC, whereas median OS was 70.1 months, in the mesothelin-positive group and 74.5 months in mesothelin-negative group, respectively. Strong correlation was seen between mesothelin expression and tumor grade in patients with TNBC (P<0.005). In a multivariable Cox proportional hazards model, mesothelin expres...Continue Reading

References

Mar 1, 1992·The American Journal of Surgical Pathology·K ChangM C Willingham
Feb 1, 1992·International Journal of Cancer. Journal International Du Cancer·K ChangM C Willingham
Jan 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·K Chang, I Pastan
Mar 18, 2003·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Nelson G Ordóñez
Oct 25, 2003·The American Journal of Surgical Pathology·Nelson G Ordóñez
Jun 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Raffit HassanIra Pastan
Dec 30, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Denise R ShawTheresa V Strong
Jan 19, 2006·American Journal of Clinical Pathology·Raffit HassanDaniel Brackett
Feb 10, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·M Jim YenIe-Ming Shih
Nov 7, 2006·IUBMB Life·Zhimin Lu, Shuichan Xu
Mar 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mitchell HoIra Pastan
Jun 22, 2007·Gene Therapy·C-L ChangC-F Hung
Oct 20, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Raffit Hassan, Mitchell Ho
Feb 19, 2008·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Oluf Dimitri RoeKristina Kjaerheim
Feb 19, 2008·Molecular Cancer Therapeutics·Min LiQizhi Yao
Sep 15, 2009·The Biochemical Journal·Ming-Cheng ChangWen-Fang Cheng
Oct 6, 2010·Journal of Cancer·Liping YuMitchell Ho
Jul 23, 2011·Journal of Surgical Oncology·Kenji BabaShoji Natsugoe
Mar 16, 2012·Breast Cancer Research and Treatment·Julia TchouPaul J Zhang
Aug 22, 2012·The Journal of International Medical Research·L WangY Wang
Jul 3, 2013·Clinical Breast Cancer·Napa ParinyanitikulAna Maria Gonzalez-Angulo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis